PCM
RPRX icon

Pinz Capital Management’s Royalty Pharma RPRX Stock Holding History

Pinz Capital Management’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-75,000
Closed -$3.64M – 173
2020
Q2 		$3.64M Buy
+75,000
New +$3.71M 1.67% 6

Other funds holding RPRX

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
HMC
Harvard Management Company Boston, Massachusetts $1.82B AUM 26.23% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Pinz Capital Management's RPRX Position: Q3 2020 in Review

Pinz Capital Management sold out of Royalty Pharma (RPRX) in Q3 2020, closing a stake of 75,000 shares — an estimated $3.64M sold.

Pinz Capital Management first reported a position in RPRX in Q2 2020 and held it in 1 quarter. The position peaked at $3.64M in Q2 2020. 134 funds tracked by Wall St. Rank hold RPRX as of Q3 2020.

  • Pinz Capital Management reported no remaining Royalty Pharma position as of Q3 2020 after selling out during the quarter.
  • Pinz Capital Management sold 75,000 Royalty Pharma shares in Q3 2020, an estimated $3.64M.
  • Pinz Capital Management first reported a position in Royalty Pharma in Q2 2020 and held it in 1 quarter.
  • Pinz Capital Management's Royalty Pharma position peaked at $3.64M in Q2 2020.
  • 134 funds tracked by Wall St. Rank held Royalty Pharma as of Q3 2020.

Based on Pinz Capital Management's 13F filing for Q3 2020, filed 16 Nov 2020.